Loss of an enzyme necessary for a process called lipoylation disrupts the way cancer cells copy their DNA, increasing their vulnerability to a class of anticancer drugs known as PARP inhibitors, according to a study led by UT Southwestern Medical Center researchers.
UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes engineered cancer-fighting immune cells behave more like stem cells, improving their therapeutic effectiveness. The study suggests new strategies for improving the efficacy of these immune cells, known as chimeric antigen receptor T cells.
